press release Nov. 13, 2012, 7:01 a.m. EST Commercial

New Post Public Reply Private Reply Replies (0) Message Board
Depcom

press release

Nov. 13, 2012, 7:01 a.m. EST

Commercial Pipeline Field Testing in China Confirms Laboratory Results of STWA's Oil Pipeline Efficiency Technology

AOT(TM) 1.3vx Completes Phase II Testing on Active Commercial Pipeline Located on the Daqing Oilfield in Northeastern China

 

 

 

SANTA BARBARA, CA, Nov 13, 2012 (MARKETWIRE via COMTEX) -- STWA, Inc. /quotes/zigman/156067 /quotes/nls/zero ZERO +1.02% ("STWA" or the "Company"), a developer of applied solutions for oil and fuel delivery systems in the multi-billion dollar oil pipeline and diesel engine markets, announced today that the Company's groundbreaking oil pipeline energy-efficiency system known as Applied Oil Technology(TM), (AOT(TM)) has completed its Phase II testing in China operating for a full week on an active commercial production pipeline located in Daqing, Heilongjian Province, Northeastern China, near the Russian Siberian border and outer Mongolia.

The Company was pleased with the testing and will release third party results from test partners in China if and when they are authorized to be published. "The reports are saying that after initial setup, the AOT(TM) pre-production prototype, designated as version 1.3vx due to modifications for this specific application, performed as designed at continuous power duty for a week straight, 24 hours per day, starting and stopping on demand without incident," stated STWA CEO Mr. Cecil Bond Kyte. "The test reports coming in from the oilfield are confirmation that the high-temperature operation of the device successfully mirrored the laboratory test results generated in the lab during September testing. We at STWA would like to thank our Chinese affiliates for the collaboration and joint efforts to make this commercial installation and testing a success." STWA spearheaded the project, providing considerable time and resources, a ground installation supervisory and testing crew, detailed parameters, procedures and protocols, and all logistics to transport the USA-made AOT(TM) 1.3vx prototype and necessary installation equipment from the United States to the Daqing Oilfield in northeastern China."

Testing was conducted as a joint effort between STWA, Temple University, Heng He Xing Ye Technology Development Corporation (TDC), a Chinese government pipeline agency, and Daqing Oilfield Limited Company (DOC).

This Phase II field-testing was originally scheduled to be conducted as a flow-loop test at the CPP pipeline flow assurance facility in Tianjin, China, 86 miles southeast of Beijing. The testing location was modified by our Chinese affiliates and moved from the flow loop to an active production oilfield pipeline, located at the Daqing oilfield 900 miles northeast of Beijing. The location change was initiated in order to accelerate the testing and acceptance procedures of the new technology for national use. The Daqing oilfield is operated by Daqing Oilfield Limited Company, and is China's largest oilfield, currently ranked in the top five largest oilfields in the world.

Based on the site change for the testing location, certain logistical modifications needed to be made by STWA. The U.S. testing team scheduled their trip to arrive in Mainland China the week of October 22, 2012, to assist with installation and testing. STWA executive management followed the testing team for meetings in China and returned to the corporate offices from China on November 8, 2012.

Based on the successful testing of AOT(TM) with the United States Department of Energy at the Rocky Mountain Oilfield Testing Center throughout 2011 and early 2012 as well as recent commercial interest in the technology, STWA established installation instructions and an operator's manual. In addition to this, the team created a detailed set of testing parameters, protocols, and procedures for the testing in China. The purpose was to analyze and compare the test data and results generated by the field-scale prototype as further confirmation of the high-temperature testing conducted at Temple University with samples of the crude from the particular test field.

The original Chinese testing parameters conducted at the CPP Flow Assurance R&D Center during June, 2012, were conducted at low-temperature ranges for confirmation of the scientific effect on the oil. The high-temperature testing at Temple University during September 2012, was to confirm the scientific effect at the operating temperatures experienced during full-scale operation in the particular oilfield. The commercial active pipeline testing conducted at the Daqing oilfield in October 2012, was to confirm the scientific effect's parity from laboratory testing to the commercial operating parameters as experienced in the field. The parity was successful.

The testing of the AOT(TM) 1.3vx prototype successfully demonstrated similar viscosity reduction results generated by the Temple University laboratory high-temperature, 55 degrees C (131 degrees F) to 90 degrees C (194 degrees F) testing in September, 2012. The particular oil from the Daqing oilfield is heated to the high temperatures during production and transportation to counteract the high viscosity nature of the crude oil, which turns to solid form at temperatures below 33 degrees C (91.4 degrees F). The successful testing results confirm the accuracy of the laboratory viscosity reduction results for the particular crude grade, at the desired operating temperatures as experienced in the field.

Due to the successful recent Phase II field testing conducted by the parties on the Daqing oilfield active commercial pipeline, the Chinese government pipeline agency has authorized STWA to continue testing in the People's Republic of China as part of the mutually agreed upon third and final testing phase. Part of this agreement is for the Chinese agency to send a variety of oil samples at various APIs to Temple University for additional laboratory testing for further market validation.

About STWA, Inc.

STWA, Inc. develops and commercializes energy efficiency technologies that assist in meeting increasing global energy demands and improving the economics of oil extraction and transport. The Company's intellectual property portfolio includes 41 domestic and international patents and patents pending, which have been developed in conjunction with and exclusively licensed from Temple University. STWA's technologies include Applied Oil Technology(TM) (AOT(TM)), which is designed to improve oil flow through pipelines. AOT(TM) has been proven in U.S. Department of Energy tests to increase the energy efficiency of oil pipeline pump stations. ELEKTRA(TM) improves diesel engine efficiency for industrial diesel engines, as well as diesel-powered trucks, trains, marine vessels, military fleets and jet turbines. More information including a company Fact Sheet, logos and media articles are available at: http://www.stwa.com .

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2151298

 
         
        Investor Relations Contacts:
        Mr. Andrew Haag
        Managing Partner
        IRTH Communications, LLC
        Tel: +1-866-976-IRTH (4784)
        E-Mail: Email Contact
 
www.irthcommunications.com     
www.stwa.com            
        Mr. Jeremy Roe
        Managing Partner
        Integra Consulting Group, LLC
        Tel: +1-925-262-8305
        E-Mail: Email Contact
 
www.integraconsultinggroup.com            
        
        


   

SOURCE: Save The World Air, Inc.

 
  
http://www2.marketwire.com/mw/emailprcntct?id...4B2E3FBF80     
http://www.irthcommunications.com/     
http://www.stwa.com/     
http://www2.marketwire.com/mw/emailprcntct?id...4BD6D6BAA7     
http://www.integraconsultinggroup.com/            

QS Energy Inc. (QSEP) Stock Research Links

QSEP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 75

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 176

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 324

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 90

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 345

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 209

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Earnings Forecast and Expectations for Anika Therapeutics

Updated Category News Views 118

Understanding Anika Therapeutics's Upcoming Earnings Anika Therapeutics (NASDAQ: ANIK) is scheduled to unveil its quarterly earnings report soon. This anticipation is palpable amongst investors who are eager to discover the latest financial insights that the company has to offer. As the date approaches, many are analyzing the potential earnings and what they might mean...

Continue Reading
QYOU Media's Strategic Shift Towards a Creator-Focused Future

Updated Category News Views 202

QYOU Media Completes Sale of Q TV Broadcast Channel QYOU Media Inc., a leading player in the global creator economy, has successfully completed the sale of its free-to-air broadcast channel known as Q TV. This strategic move, executed through its subsidiary QYOU Media India Pvt. Ltd., marks a significant shift towards embracing new growth avenues focused on social media...

Continue Reading
Understanding Recent Disclosures from Octopus Investments

Updated Category News Views 106

Key Disclosure Information by Octopus Investments PUBLIC DISCLOSURE OF INVESTMENT INTERESTS In line with market regulations, Octopus Investments Ltd reveals crucial data regarding interests in relevant securities, particularly concerning Marlowe plc. This disclosure adheres to Rule 8.3 of the Takeover Code, aimed at maintaining transparency in the investment community....

Continue Reading
LiTime's Innovative Battery Solutions Shine in European RV Market

Updated Category News Views 297

LiTime Introduces H190 Series Batteries for RV Enthusiasts At a recent trade show, LiTime made quite the impression with its first participation in Europe’s premier RV exhibition, the Il Salone del Camper. The event, which boasts a large turnout, allowed the company to spotlight its innovative H190 series of batteries tailored for motorhomes. Targeted Designs for Unique...

Continue Reading
Oncolytics Biotech Appoints Jared Kelly as New CEO to Lead Growth

Updated Category News Views 263

Oncolytics Biotech Welcomes New Leadership for Future Growth Oncolytics Biotech Inc. (NASDAQ: ONCY), a notable player in the clinical-stage biotechnology sector focused on immunotherapy for cancer treatment, has proudly appointed Jared Kelly as its new Chief Executive Officer and as a member of its Board of Directors. This significant transition marks a pivotal moment for...

Continue Reading